Transforming drug development with synthetic biology and AI
- PMID: 38383215
- DOI: 10.1016/j.tibtech.2024.01.008
Transforming drug development with synthetic biology and AI
Abstract
The COVID-19 pandemic has thrust RNA as a platform for drug development into the spotlight. However, identifying promising drug candidates is challenging. With advances in synthetic biology and artificial intelligence (AI) models, we can overcome this hurdle, transforming drug development and ushering in a new era in the pharmaceutical industry.
Keywords: RNA; artificial intelligence; drug development; synthetic biology.
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of interests C.H.J. and J.M.T. are employees of Pfizer Inc. and may hold stock or stock options in the company. A.H. is an employee of Bulmore Consulting, which received funding from Pfizer in connection with the development of this manuscript.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources